SEC Tracker
Get the app
Person · CIK 1899977

Mark C. Schneyer

EVP at Acadia Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$3.4M
Noticed on Form 144$1M
Bought on Form 4$0
Companies1

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Acadia Pharmaceuticals ACADCommon StockDirectly71,322Oct 30, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACADStock Option (Right to Buy)
exercise $17.84, expires Mar 24, 2034, into Common Stock
Directly60,423Aug 6, 2026 · Filing · EDGAR

Sold and noticed by quarter

Mark C. Schneyer: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2022 to Q4 2026$637K$0Q1 2022: notice not machine-readableQ1 2022: $13K sold on Form 4Q2 2022: notice not machine-readableQ2 2022: $12K sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: notice not machine-readableQ1 2023: $11K sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $404K sold on Form 4Q3 2023: $293K noticed on Form 144Q3 2023: $290K sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $116K sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $116K sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $122K sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $149K sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $172K sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $69K sold on Form 4Q2 2025: $35K noticed on Form 144Q2 2025: $141K sold on Form 4Q3 2025: $557K noticed on Form 144Q3 2025: $637K sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $243K sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $159K sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $137K sold on Form 4Q3 2026: $159K noticed on Form 144Q3 2026: $587K sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $69K sold on Form 4Q1 2022Q1 2023Q1 2024Q1 2025Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2026$69K—
Q3 2026$587K$159K
Q2 2026$137K—
Q1 2026$159K—
Q4 2025$243K—
Q3 2025$637K$557K
Q2 2025$141K$35K
Q1 2025$69K—
Q4 2024$172K—
Q3 2024$149K—
Q2 2024$122K—
Q1 2024$116K—
Q4 2023$116K—
Q3 2023$290K$293K
Q2 2023$404K—
Q1 2023$11KNot machine-readable
Q2 2022$12KNot machine-readable
Q1 2022$13KNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Acadia Pharmaceuticals ACAD · Piper Sandler · 10b5-1 plan adopted May 19, 2025 · 2 notices
Aug 5, 20265,849 · ~$159KAug 5, 2026Sold as noticed Sold 5,849 at $29.00 on Aug 5 · $170K Form 4Filing · EDGAR
Aug 18, 202522,000 · ~$557KAug 18, 2025Sold as noticed Sold 22,000 at $25.18 on Aug 18 · $554K Form 4Filing · EDGAR
Acadia Pharmaceuticals ACAD · Piper Sandler · 10b5-1 plan adopted May 30, 2024 · 1 notice
May 16, 20252,000 · ~$35KMay 16, 2025Sold as noticed Sold 2,000 at $25.00 on May 16 · $50K Form 4Filing · EDGAR
Acadia Pharmaceuticals ACAD · Piper Sandler · 10b5-1 plan adopted Mar 23, 2023 · 1 notice
Aug 21, 202310,000 · ~$293KAug 21, 2023Sold as noticed Sold 10,000 at $29.00 on Aug 21 · $290K Form 4Filing · EDGAR
Sales without a matching Form 144 · 28 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,321 at $20.88 on Oct 30, 2026 · $69K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 9,292 at $29.34 on Aug 6, 2026 · $273K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 5,000 at $29.00 on Aug 6, 2026 · $145K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,506 at $21.79 on May 4, 2026 · $76K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 2,709 at $22.20 on Apr 7, 2026 · $60K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 37 at $21.72 on Mar 26, 2026 · $804 (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,171 at $21.65 on Mar 26, 2026 · $69K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 4,177 at $21.47 on Mar 25, 2026 · $90K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 10,262 at $23.69 on Nov 18, 2025 · $243K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,498 at $23.65 on Sep 15, 2025 · $83K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,498 at $14.60 on May 2, 2025 · $51K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 2,708 at $14.82 on Apr 8, 2025 · $40K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,171 at $17.05 on Mar 26, 2025 · $54K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 773 at $19.96 on Feb 24, 2025 · $15K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 10,259 at $16.81 on Nov 19, 2024 · $172K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 9,733 at $15.28 on Aug 19, 2024 · $149K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 975 at $14.79 on Jun 10, 2024 · $14K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 3,503 at $16.94 on May 2, 2024 · $59K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 2,716 at $17.87 on Apr 8, 2024 · $49K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 5,434 at $17.90 on Mar 27, 2024 · $97K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 772 at $24.67 on Feb 26, 2024 · $19K (10b5-1 plan)Filing · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 5,108 at $22.64 on Nov 20, 2023 · $116KFiling · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 974 at $25.02 on Jun 8, 2023 · $24KFiling · EDGAR
———Sold without notice Acadia Pharmaceuticals (ACAD): Sold 15,310 at $22.50 on May 17, 2023 · $344KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 1,916 at $18.16 on Apr 6, 2023 · $35KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 577 at $18.78 on Feb 24, 2023 · $11KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 653 at $17.91 on Jun 9, 2022 · $12KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 553 at $23.80 on Feb 23, 2022 · $13KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Acadia Pharmaceuticals ACAD EVP, chief financial officer · filings 2021 to 2026 · sold $3.4M · $1M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Oct 30, 2026Sale under a 10b5-1 plan−3,321$20.88$69K71,322 directFiling · EDGAR
Oct 15, 2026Grant or award from the company+6,81574,643 directFiling · EDGAR
Aug 6, 2026Option or RSU exercised or converted+14,292$17.84$255K82,120 directFiling · EDGAR
Aug 6, 2026Sale under a 10b5-1 plan−5,000$29.00$145K77,120 directFiling · EDGAR
Aug 6, 2026Sale under a 10b5-1 plan−9,292$29.34$273K67,828 directFiling · EDGAR
Aug 6, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−14,29260,423 directFiling · EDGAR
Aug 5, 2026Option or RSU exercised or converted+5,849$17.84$104K73,677 directFiling · EDGAR
Aug 5, 2026Sale under a 10b5-1 plan−5,849$29.00$170K67,828 directFiling · EDGAR
Aug 5, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−5,84974,715 directFiling · EDGAR
May 4, 2026Sale under a 10b5-1 plan−3,506$21.79$76K66,145 directFiling · EDGAR
May 1, 2026Option or RSU exercised or converted+6,81569,651 directFiling · EDGAR
May 1, 2026Option or RSU exercised or converted
Restricted Stock Units
−6,8156,815 directFiling · EDGAR
Apr 7, 2026Sale under a 10b5-1 plan−2,709$22.20$60K62,836 directFiling · EDGAR
Apr 5, 2026Option or RSU exercised or converted+5,27665,545 directFiling · EDGAR
Apr 5, 2026Option or RSU exercised or converted
Restricted Stock Units
−5,2760 directFiling · EDGAR
Mar 26, 2026Sale under a 10b5-1 plan−3,171$21.65$69K60,306 directFiling · EDGAR
Mar 26, 2026Sale under a 10b5-1 plan−37$21.72$80460,269 directFiling · EDGAR
Mar 25, 2026Sale under a 10b5-1 plan−4,177$21.47$90K57,299 directFiling · EDGAR
Mar 25, 2026Option or RSU exercised or converted+6,17863,477 directFiling · EDGAR
Mar 25, 2026Option or RSU exercised or converted
Restricted Stock Units
−6,17812,358 directFiling · EDGAR
Mar 24, 2026Option or RSU exercised or converted+8,13861,476 directFiling · EDGAR
Mar 24, 2026Option or RSU exercised or converted
Restricted Stock Units
−8,13824,414 directFiling · EDGAR
Mar 6, 2026Grant or award from the company
Stock Option (Right to Buy)
+90,69190,691 directFiling · EDGAR
Mar 6, 2026Grant or award from the company
Restricted Stock Units
+26,38226,382 directFiling · EDGAR
Nov 18, 2025Sale under a 10b5-1 plan−10,262$23.69$243K53,338 directFiling · EDGAR
Nov 17, 2025Option or RSU exercised or converted+9,91353,687 directFiling · EDGAR
Nov 17, 2025Option or RSU exercised or converted+9,91363,600 directFiling · EDGAR
Nov 17, 2025Option or RSU exercised or converted
Restricted Stock Units
−9,9130 directFiling · EDGAR
Nov 17, 2025Option or RSU exercised or converted
Restricted Stock Units
−9,9130 directFiling · EDGAR
Sep 15, 2025Sale under a 10b5-1 plan−3,498$23.65$83K43,447 directFiling · EDGAR
Sep 12, 2025Grant or award from the company+6,81546,945 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−22,000$25.18$554K40,130 directFiling · EDGAR
May 16, 2025Sale under a 10b5-1 plan−2,000$25.00$50K62,130 directFiling · EDGAR
May 2, 2025Sale under a 10b5-1 plan−3,498$14.60$51K62,773 directFiling · EDGAR
May 1, 2025Option or RSU exercised or converted+6,81566,271 directFiling · EDGAR
May 1, 2025Option or RSU exercised or converted
Restricted Stock Units
−6,81513,630 directFiling · EDGAR
Apr 8, 2025Sale under a 10b5-1 plan−2,708$14.82$40K59,456 directFiling · EDGAR
Apr 5, 2025Option or RSU exercised or converted+5,27562,164 directFiling · EDGAR
Apr 5, 2025Option or RSU exercised or converted
Restricted Stock Units
−5,2755,276 directFiling · EDGAR
Mar 26, 2025Sale under a 10b5-1 plan−3,171$17.05$54K56,889 directFiling · EDGAR
Mar 25, 2025Option or RSU exercised or converted+6,17860,060 directFiling · EDGAR
Mar 25, 2025Option or RSU exercised or converted
Restricted Stock Units
−6,17818,536 directFiling · EDGAR
Mar 24, 2025Grant or award from the company
Stock Option (Right to Buy)
+110,761110,761 directFiling · EDGAR
Mar 24, 2025Grant or award from the company
Restricted Stock Units
+32,55232,552 directFiling · EDGAR
Feb 24, 2025Sale under a 10b5-1 plan−773$19.96$15K53,882 directFiling · EDGAR
Feb 23, 2025Option or RSU exercised or converted+1,35354,655 directFiling · EDGAR
Feb 23, 2025Option or RSU exercised or converted
Restricted Stock Units
−1,3530 directFiling · EDGAR
Nov 19, 2024Sale under a 10b5-1 plan−10,259$16.81$172K53,302 directFiling · EDGAR
Nov 17, 2024Option or RSU exercised or converted+9,91353,648 directFiling · EDGAR
Nov 17, 2024Option or RSU exercised or converted+9,91363,561 directFiling · EDGAR
Nov 17, 2024Option or RSU exercised or converted
Restricted Stock Units
−9,9139,913 directFiling · EDGAR
Nov 17, 2024Option or RSU exercised or converted
Restricted Stock Units
−9,9139,913 directFiling · EDGAR
Aug 19, 2024Sale under a 10b5-1 plan−9,733$15.28$149K43,735 directFiling · EDGAR
Aug 16, 2024Grant or award from the company+5,27539,839 directFiling · EDGAR
Aug 16, 2024Grant or award from the company+13,62953,468 directFiling · EDGAR
Jun 10, 2024Sale under a 10b5-1 plan−975$14.79$14K34,564 directFiling · EDGAR
Jun 8, 2024Option or RSU exercised or converted+1,89335,539 directFiling · EDGAR
Jun 8, 2024Option or RSU exercised or converted
Restricted Stock Units
−1,8930 directFiling · EDGAR
May 2, 2024Sale under a 10b5-1 plan−3,503$16.94$59K32,053 directFiling · EDGAR
May 1, 2024Option or RSU exercised or converted+6,81435,556 directFiling · EDGAR

41 earlier transactions are in the filing list below.

All 36 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Oct 30, 2026Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 7, 2026Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 5, 2026Form 144Acadia Pharmaceuticals ACADFiling · EDGAR
May 5, 2026Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Apr 7, 2026Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Mar 26, 2026Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Mar 10, 2026Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Nov 19, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Sep 16, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 19, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 18, 2025Form 144Acadia Pharmaceuticals ACADFiling · EDGAR
May 19, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
May 16, 2025Form 144Acadia Pharmaceuticals ACADFiling · EDGAR
May 2, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Apr 8, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Mar 26, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Feb 25, 2025Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Nov 19, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 20, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Jun 11, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
May 3, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Apr 9, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Mar 27, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Feb 27, 2024Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Nov 21, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 23, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Aug 21, 2023Form 144Acadia Pharmaceuticals ACADFiling · EDGAR
Jun 12, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
May 19, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
May 3, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Apr 7, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Feb 27, 2023Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Jun 10, 2022Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Apr 7, 2022Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Feb 25, 2022Form 4Acadia Pharmaceuticals ACADFiling · EDGAR
Dec 20, 2021Form 3Acadia Pharmaceuticals ACADFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.